Akeso says Phase III HARMONi-2 trial shows ivonescimab beats pembrolizumab on PFS

• Akeso reported April 28, 2026 that ivonescimab gained upgraded recommendations in 2026 CSCO guideline for non-small cell lung cancer, strengthening its positioning in first-line treatment.
• Phase III HARMONi-2 results were already presented in guideline update, supporting ivonescimab monotherapy as preferred option versus pembrolizumab in PD-L1-positive disease.
• Phase III HARMONi-6 results were cited as positive, supporting ivonescimab with chemotherapy in first-line squamous disease, with regulatory review ongoing for this use.
• Guideline update also maintained ivonescimab with chemotherapy as recommended option for EGFR-mutant disease following resistance, supporting broader commercial reach across treatment lines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604280407PR_NEWS_USPR_____CN45278) on April 28, 2026, and is solely responsible for the information contained therein.